Preventing the Inflammatory Response to Experimentally-induced Insomnia Symptoms
| Status: | Recruiting |
|---|---|
| Conditions: | Insomnia Sleep Studies |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 35 |
| Updated: | 8/17/2016 |
| Start Date: | October 2014 |
| End Date: | December 2016 |
| Contact: | Jennifer Scott-Sutherland, MA |
| Email: | jscottsu@bidmc.harvard.edu |
| Phone: | 617-667-5243 |
The main purpose of this study is to learn about the effects of sleep disruption (two days
in a row where sleep is shortened and disrupted) on inflammation, mood (how you feel), and
pain processing (your own experiences/perceptions of pain). In this research project, we are
trying to figure out if we can change the effects of sleep disruption on inflammation, mood,
and pain. Therefore, we will study whether taking a low-dose aspirin pill every day over 2
weeks can change how we respond to sleep disruption. For example, does the sensitivity to
pain (e.g., how intense the feeling of pain is if we put our hand in very hot or very cold
water) change with sleep disruption, and can low-dose aspirin influence this change. We are
also interested in seeing how inflammation changes in relation to your own perceived
experience of pain.
in a row where sleep is shortened and disrupted) on inflammation, mood (how you feel), and
pain processing (your own experiences/perceptions of pain). In this research project, we are
trying to figure out if we can change the effects of sleep disruption on inflammation, mood,
and pain. Therefore, we will study whether taking a low-dose aspirin pill every day over 2
weeks can change how we respond to sleep disruption. For example, does the sensitivity to
pain (e.g., how intense the feeling of pain is if we put our hand in very hot or very cold
water) change with sleep disruption, and can low-dose aspirin influence this change. We are
also interested in seeing how inflammation changes in relation to your own perceived
experience of pain.
Sleep that is deficient in quantity or quality leads to upregulation of inflammatory markers
(Mullington et al., 2010). In particular, interleukin (IL)-6 and prostaglandin (PG) E2 are
elevated in experimental models of sleep restriction or total sleep deprivation, as well as
in insomnia. Inflammation is thought to be a key mechanism through which insufficient sleep
increases the risk of developing or exacerbating various disorders, including cardiovascular
and metabolic disorders (Mullington et al., 2009), as well as pain-related disorders (Haack
et al., 2009c). With respect to pain, markers such as IL-6 and PGE2 are able to sensitize
pain transmission neurons, thereby increasing their responsiveness to stimulation. In the
context of insufficient sleep, both IL-6 and PGE2 have been shown to be associated with
increased spontaneous pain (Haack et al., 2007;Haack et al., 2009a), suggesting their
mediating role in pain amplification as a consequence of insufficient sleep.
These findings raise the question of whether pain amplification can be dampened by
preventing the inflammatory increase in response to insufficient sleep.
The primary goal of this pilot project is to gather preliminary support for the hypothesis
that deficient sleep leads to pain amplification through an inflammatory mechanism.
In addition to the primary goal of this proposal, the secondary goal is to gather
preliminary data on the effects of aspirin on blood pressure regulation. Cardiovascular
disease is the leading cause of death in the United States. A modest reduction of blood
pressure (BP; i.e., 3 to 5 mmHg) in the population will produce a significant fall in
serious cardiovascular events (Turnbull, 2003). It has been reported that low-dose aspirin
may significantly reduce BP (i.e., 6 to 7 mmHg) when taken at bedtime (Hermida et al.,
1994;Hermida et al., 1997;Hermida et al., 2003b;Hermida et al., 2003a;Hermida et al.,
2005a;Hermida et al., 2005b). Aspirin, when taken at bedtime, may modulate 24h blood
pressure by decreasing the nocturnal rise of renin-angiotensin-aldosterone system (RAAS)
activity (Snoep et al., 2009) and attenuating the nocturnal drop in nitric oxide (NO)
production (Hermida et al., 2005b). However, the underlying mechanisms are still unknown.
Therefore, the second goal of this pilot project is to investigate the potential mechanisms
contributing to BP reduction in response to aspirin taken at bedtime.
(Mullington et al., 2010). In particular, interleukin (IL)-6 and prostaglandin (PG) E2 are
elevated in experimental models of sleep restriction or total sleep deprivation, as well as
in insomnia. Inflammation is thought to be a key mechanism through which insufficient sleep
increases the risk of developing or exacerbating various disorders, including cardiovascular
and metabolic disorders (Mullington et al., 2009), as well as pain-related disorders (Haack
et al., 2009c). With respect to pain, markers such as IL-6 and PGE2 are able to sensitize
pain transmission neurons, thereby increasing their responsiveness to stimulation. In the
context of insufficient sleep, both IL-6 and PGE2 have been shown to be associated with
increased spontaneous pain (Haack et al., 2007;Haack et al., 2009a), suggesting their
mediating role in pain amplification as a consequence of insufficient sleep.
These findings raise the question of whether pain amplification can be dampened by
preventing the inflammatory increase in response to insufficient sleep.
The primary goal of this pilot project is to gather preliminary support for the hypothesis
that deficient sleep leads to pain amplification through an inflammatory mechanism.
In addition to the primary goal of this proposal, the secondary goal is to gather
preliminary data on the effects of aspirin on blood pressure regulation. Cardiovascular
disease is the leading cause of death in the United States. A modest reduction of blood
pressure (BP; i.e., 3 to 5 mmHg) in the population will produce a significant fall in
serious cardiovascular events (Turnbull, 2003). It has been reported that low-dose aspirin
may significantly reduce BP (i.e., 6 to 7 mmHg) when taken at bedtime (Hermida et al.,
1994;Hermida et al., 1997;Hermida et al., 2003b;Hermida et al., 2003a;Hermida et al.,
2005a;Hermida et al., 2005b). Aspirin, when taken at bedtime, may modulate 24h blood
pressure by decreasing the nocturnal rise of renin-angiotensin-aldosterone system (RAAS)
activity (Snoep et al., 2009) and attenuating the nocturnal drop in nitric oxide (NO)
production (Hermida et al., 2005b). However, the underlying mechanisms are still unknown.
Therefore, the second goal of this pilot project is to investigate the potential mechanisms
contributing to BP reduction in response to aspirin taken at bedtime.
Inclusion Criteria:
- Women and men between the ages 18-35 years
- Body mass index (BMI) between 18.5 and 30.0 kg/m2
- For female participants: regular menstrual cycles, no significant discomfort during
pre-menses/menses
- Daily sleep duration between 7.0-9.0 hours, verified by sleep log/actigraphy data for
two weeks
- Habitual sleep period must begin within one hour of 2300h (to ensure normal
entrainment)
- Blood chemistry in the normal range
Exclusion Criteria:
- Active infection/disease.
- History of psychiatric, neurological, pain-related, immune, gastrointestinal, or
cardiovascular disease; significant allergy; Raynaud's syndrome.
- History of intolerance or allergy to non-steroidal anti-inflammatory drugs (NSAID)
- Esophageal reflux; gastric or duodenal ulcers; or asthma
- Pregnant/nursing.
- Respiratory disturbance index of >5 events/hour on polysomnographic sleep study,
periodic leg movement index (PLMI) >15/hour; sleep efficiency <80% (findings
indicative of a sleep disorder).
- Regular medication use other than oral contraceptives.
- Donation of blood or platelets 3 month prior to or in-between in-hospital visits.
- Substance abuse.
We found this trial at
1
site
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
